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ABSTRACT
Aims: To assess the prognostic importance of high-
sensitive C reactive protein (hsCRP) in patients with
mild to moderate aortic valve stenosis during placebo or
simvastatin/ezetimibe treatment in Simvastatin and
Ezetimibe in Aortic Stenosis (SEAS).
Methods and results: In 1620 SEAS patients, we
measured lipids and hsCRP at baseline and after 1 year
of treatment and registered during 4 years of follow-up
major cardiovascular events (MCE) composed of
ischaemic cardiovascular events (ICE) and aortic valve-
related events (AVE). Simvastatin/ezetimibe reduced
low-density lipoprotein cholesterol (3.49 (2.94 to 4.15)
to 1.32 (1.02 to 1.69) vs 3.46 (2.92 to 4.08) to 3.34
(2.81 to 3.92) mmol/L) and hsCRP (2.1 (0.9 to 4.1) to
1.2 (0.6 to 2.4) vs 2.2 (0.9 to 4.9) to 1.8 (0.85 to
4.35) mg/L, all p<0.05) during the first year of
treatment. In multivariable Cox regression analysis
adjusting for traditional risk factors and baseline hsCRP,
ICE was associated with a 1-year increase of hsCRP
(HR=1.19 (95% CI 1.12 to 1.25), p<0.001) but not with
active treatment (HRTreatment=0.86 (0.67 to 1.13),
p=0.28). Patients in the top quartile of baseline hsCRP
versus the rest were associated with a higher risk of
MCE (HR=1.34(1.09 to 1.64), p=0.02). The prognostic
benefit of reduction in hsCRP after 1 year was
significantly larger (p<0.01 for interaction) in patients
with high versus low baseline hsCRP; hence, a
reduction in hsCRP abolished the difference in
incidence of MCE between high versus low baseline
hsCRP in patients with reduced hsCRP (31.1 vs 31.9%,
NS) in contrast to patients with increased hsCRP.
Conclusions: The treatment-associated reduction in
ICE was in part related to a reduction in hsCRP but not
in lipids. hsCRP reduction was associated with less
MCE, especially in patients with high baseline hsCRP.
Trial registration: NCT00092677.
INTRODUCTION
The role of inﬂammation in the pathogen-
esis of aortic valve disease remains unclear.
Therefore, we investigated the prognostic
importance of baseline high-sensitive C react-
ive protein (hsCRP) and changes in hsCRP
during the ﬁrst year of lipid lowering with
simvastatin 40 mg and ezetimibe 10 mg
KEY QUESTIONS
What is already known about this subject?
▸ Little is known concerning this subject. The
present study is, to the best of our knowledge, the
first study to test the prognostic importance of
in-treatment changes in high-sensitive C reactive
protein (hsCRP). In the smaller ASTRONOMER
study, hsCRP was measured at year 1 as well, but
these data have not been utilised.
What does this study add?
▸ In our study, alterations in hsCRP are a stronger
predictor of outcome than baseline hsCRP. We
demonstrate that a reduction in hsCRP is asso-
ciated with an improved prognosis, resembling
that of patients with low baseline and low 1-year
hsCRP.
▸ In the Simvastatin and Ezetimibe in Aortic
Stenosis (SEAS) study, lipid-lowering treatment
did not reduce the primary, combined end point,
but a 22% reduction in ischaemic events was
observed. This reduction in ischaemic events
was associated with a reduction in hsCRP, but
not in lipids. This is in line with findings from
the JUPITER trial, but has not previously been
shown in patients with aortic stenosis.
How might this impact on clinical practice?
▸ We believe that better knowledge about the
importance of inflammation in patients with
aortic stenosis may improve risk stratification,
making disease monitoring more individualised
and better targeted and preventing morbidity
and mortality in patients with aortic stenosis.
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versus placebo in the Simvastatin and Ezetimibe in
Aortic Stenosis (SEAS) study. The SEAS study tested if
simvastatin and ezetimibe in combination could reduce
the need for aortic valve replacement (AVR). The study
was neutral in reducing major cardiovascular events
(MCE) consisting of both aortic valve-related events
(AVE) and ischaemic cardiovascular events (ICE), but a
22% reduction in ICE in the treatment group was
shown.1 This reduction primarily consisted of a reduc-
tion in coronary artery bypass grafting (CABG).2
Cholesterol and inﬂammation are involved in the
development of atherosclerosis and subsequent cardio-
vascular disease.3 4 4a 4b 4c Histology of stenotic aortic
valves shows subendothelial plaque-like lesions on the
aortic side of the leaﬂets that resemble those seen in ath-
erosclerosis and ‘atherogenic’ lipoproteins are accumu-
lated in the lesions.5 6 hsCRP has shown its potential as a
predictor of cardiovascular disease in several
studies.7 8 8a 8b 8c Therefore, we hypothesised that a
reduction in hsCRP would be associated with fewer
ischaemic events, in line with ﬁndings from the JUPITER
trial,9 and we also wanted to explore if a reduction of
hsCRP would be associated with fewer MCE in this aortic
stenosis (AS) population.
METHODS
Study population
The SEAS study was a multicentre, randomised, double-
blind, placebo-controlled study investigating whether
intensive lipid lowering with simvastatin/ezetimibe com-
bination versus placebo could reduce the need for AVR
and risk of cardiovascular morbidity and mortality in
1873 patients aged 45–85 years with asymptomatic AS
(deﬁned as echocardiographic aortic valve thickening
accompanied by a Doppler-measured aortic peak ﬂow
velocity >2.5 and <4 m/s and normal left ventricular
(LV) systolic function). For this substudy, we included
1620 patients with hsCRP analysed at baseline. In total,
253 patients were excluded for missing baseline values
of hsCRP. There were no differences between the study
population and the 253 excluded patients with regard
to age, gender, treatment and tobacco use. The com-
plete study protocol, study design, organisation, clinical
measures, exclusion criteria (most importantly, systolic
heart failure, diabetes mellitus and known ischaemic
heart disease) and baseline characteristics have been
published previously.1 10 All patients gave written
informed consent, and ethics committees in all partici-
pating countries approved the study (the SEAS trial
is registered at http://ClinicalTrials.gov, identiﬁer
NCT00092677).
High-sensitive C reactive protein
hsCRP was measured at baseline and at 1 year after
inclusion. Serum hsCRP concentration was determined
using a particle-enhanced immunoturbidimetry assay
(Roche/Hitachi) range 0.1–20 mg/L and lowest
detection limit 0.03 mg/L. A 1 year increase in hsCRP
was deﬁned as a rise from baseline to year 1.
White cell count and lipids
White cell counts (WCCs) were measured only at base-
line and lipids were measured at baseline, and then
every 6 months during follow-up. All blood samples were
analysed by the central laboratory, PPD Global Central
Labs, in Belgium. Study investigators were blinded to
lipid values throughout the entire study.
Hypertension and tobacco
Hypertension was deﬁned in the SEAS study as a history
of hypertension or the use of antihypertensive medica-
tion.11 This was reported by an attending physician or an
elevated blood pressure at the baseline clinical visit (sys-
tolic blood pressure ≥140 mm Hg and/or diastolic blood
pressure ≥90 mm Hg), in accordance with the European
Society of Hypertension Guidelines.12 Tobacco status was
self-evaluated at study entrance.
ECG
The speciﬁcs about protocol, reading and reproducibility
have been published previously.13 In short, ECGs were
recorded at baseline and then annually at the local study
centres, after which they were sent to the central ECG
core laboratory at The Heart Center, Rigshospitalet,
Denmark. A physician blinded to the randomisation and
clinical data read and transferred all ECGs directly to a
database by use of the Minnesota codes.13
Echocardiogragraphy
The study protocol has been published earlier.14 In short,
echocardiography was performed at baseline, once a
year and before valve surgery if needed. Echocardiography
was performed according to a standardised echocardio-
graphic protocol. All images were read at the SEAS
Echocardiography Core Laboratory at Haukeland
University Hospital in Bergen, Norway. All readings were
performed according to the American Society of
Echocardiography guidelines. The readers were unaware
of the sequence and site in order to minimise bias.
Efficacy outcomes
The SEAS study was event driven and was designed to con-
tinue until 464 events had occurred or all patients had
been followed for at least 4 years. The primary outcome
was MCE, a composite consisting of death from cardiovas-
cular causes, AVR, congestive heart failure because of
progression of AS, non-fatal myocardial infarction, hospi-
talisation for unstable angina, CABG, percutaneous coron-
ary intervention (PCI) or non-haemorrhagic stroke. MCE
included AVE and ICE. ICE was deﬁned as death from
cardiovascular causes, non-fatal myocardial infarction, hos-
pitalisation for unstable angina, CABG, PCI or non-
haemorrhagic stroke. All outcomes were classiﬁed by an
independent End-point Classiﬁcation Committee unaware
of study group assignment.1
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Statistical analyses
Baseline characteristics are presented as mean±SD for con-
tinuous variables and proportions for categorical variables.
Non-Gaussian distributed variables are presented as
median values and IQR. hsCRP was log2 transformed in
order to fulﬁl model assumptions in statistical analyses.
Log2 was used to evaluate the risk associated with doubling
of the concentration. Changes (1 year) in hsCRP are
reported as the 1-year value minus baseline hsCRP.
Unpaired Student t test was used to determine differences
between treatment groups and paired Student t test was
used to determine changes during treatment within each
treatment group for normally distributed variables. For
non-Gaussian distributed variables, Mann-Whitney U test
and Wilcoxon signed-rank test, respectively, were used.
Differences in continuous and categorical baseline
characteristics were analysed using the one-way analysis of
variance. Correlation between baseline characteristics of
interest was explored using Spearman correlation analysis.
For outcome prediction and comparison between groups,
Kaplan-Meier plots and the log rank test were used. HRs
were assessed by multiple Cox proportional hazard ana-
lyses and presented with 95% CI. hsCRP as a variable of
interest along with gender, age and treatment allocation
were forced into the models. The other variables of inter-
est: blood pressure, body mass index (BMI), heart rate,
glucose, WCC, total and low-density lipoprotein (LDL)
cholesterol, 1-year changes in total and LDL-cholesterol,
estimated glomerular ﬁltration rate, tobacco, aspartate
aminotransferase (AST) and ejection fraction were added
to the models by backward selection. The performance of
the Cox models was summarised using C-statistics to allow
for right censoring of data and variable follow-up time.15
The two models compared were the basic model (the best
statistical performing model predicting outcome without
hsCRP and treatment forced into the model age, sex,
heart rate, WCC, tobacco and treatment group) versus the
new model (basic model plus baseline hsCRP and 1-year
changes in hsCRP). Net reclassiﬁcation improvement
(NRI) was estimated as continuous NRI and presented
with its CI and upward and downward reclassiﬁcation
rates.16 The bias-corrected 95% CIs for the C-statistics and
NRI were assessed by the usage of bootstrapping. Finally,
the integrated discrimination improvement (IDI) was cal-
culated.17 This measure can be described as the difference
in improved sensitivity and potential increase in ‘one
minus speciﬁcity’, with the new model including the
marker of interest versus the basic model.17 For all models,
a two-tailed p<0.05 was required for statistical signiﬁcance.
Statistical analyses were performed using IBM SPSS
V.20.0.0 (SPSS, Chicago, Illinois, USA) and R V.2.15.2
(R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
At baseline, the median age was 69 years (IQR 61–75;
table 1).
With ascending quartiles of hsCRP, most of the trad-
itional cardiovascular risk factors increased signiﬁcantly.
The proportion of men proportion fell with increasing
quartiles of baseline hsCRP. With increasing quartiles of
hsCRP, LV mass indexed by body surface area (baseline
Table 1 Baseline characteristics according to quartiles of baseline hsCRP
Variable
hsCRP (mg/L)
Quartiles of baseline hsCRP
p ANOVA
1st quartile
0.00–0.90
2nd quartile
0.90–2.15
3rd quartile
2.15–4.50
4th quartile
4.50–15.80
Age (year) 66±10 67±10 69±9 68±9 <0.001
Female sex (n, %) 144 (34.1) 142 (34.5) 162 (41.8) 178 (44.9) 0.002
Smoking (n, %)
Current 62 (14.7) 77 (18.7) 74 (19.1) 91 (23) 0.03
Former 150 (35.5) 147 (35.7) 144 (37.1) 143 (36.1) 0.97
Never 210 (49.8) 188 (45.6) 170 (43.8) 162 (40.9) 0.08
Hypertension 342 (81) 355(86.2) 338(87.1) 362(91.4) <0.001
Randomised treatment (n, %) 207 (49.1) 219 (53.2) 214 (55.2) 180 (45.5) 0.03
Systolic BP (mm Hg) 143±0 146±20 144±20 146±20 0.045
Diastolic BP (mm Hg) 81±10 83±10 82±11 82±10 0.36
Body mass index (kg/m2) 25±4 27±4 28±4 29±5 <0.001
Left ventricular mass index (g/m2) 99.26±30.3 102.07±30.72 102.6±32.89 104.6±32.62 0.12
Left ventricular ejection fraction (%) 66.41±8.21 65.71±8.54 65.33±7.76 65.43±8.53 0.25
Aortic valve area index (cm2/m2) 0.73±0.27 0.69±0.28 0.68±0.26 0.68±0.25 0.046
Aortic valve peak velocity (m/s) 3.25±0.64 3.24±0.65 3.27±0.65 3.25±0.64 0.96
Concomitant treatment
ACE inhibitor 80 (19) 126 (30.6) 108 (27.8) 134 (33.8) <0.001
Angiotensin II receptor blocker 72 (17.1) 82 (19.9) 67 (17.3) 86 (21.7) 0.272
Calcium antagonist 83 (19.7) 111 (26.9) 111 (28.6) 152 (38.4) <0.001
Aspirin or other platelet inhibitor 182 (43.1) 182 (44.2) 164 (42.3) 191 (48.2) 0.34
β-Blocker 173 (41) 212 (51.5) 202 (52.1) 208 (52.5) 0.002
ANOVA, analysis of variance; BP, blood pressure; hsCRP, high-sensitive C reactive protein.
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mean=102 g/m2) and aortic valve peak velocity (baseline
mean=3.05 m/s) did not increase, whereas aortic valve
area index (baseline mean=0.63 cm2/m2) did decrease
signiﬁcantly (table 1).
At baseline, hsCRP was associated with WCC (r=0.33,
p<0.001), but not with total cholesterol (r=−0.041,
p=0.10) or LDL-cholesterol (r=0.002, p=0.94). Baseline
and 1-year values of lipids, liver marker AST and inﬂam-
matory markers are shown in table 2.
At 1 year, hsCRP, total and LDL-cholesterol were lower
in the treatment group, but unchanged in the placebo
group. AST was similar in the two groups at baseline, but
increased in the treatment group.
In univariate Cox regression analyses, higher baseline
hsCRP as well as an increase in hsCRP predicted MCE as
well as ICE (table 3).
In multivariate Cox regression analyses, hsCRP values
predicted both MCE and ICE independently of each
other as well as the traditional cardiovascular risk factors
(table 3). The highest event-free survival was observed in
the two groups with reduced hsCRP values (ﬁgure 1A).
More events (MCE) occurred with increasing hsCRP at
baseline (p=0.014). However, an interaction was observed
indicating that risk was primarily conﬁned to those with
increasing hsCRP values, in contrast to those with a
decreasing hsCRP (table 4; p<0.01 for interaction).
Actually, in patients with a decrease in hsCRP during
the ﬁrst year, there was no signiﬁcant difference in event
rates in patients with high versus low baseline hsCRP
(31.1% vs 31.9%, NS). However, in patients with an
increase in hsCRP, a higher MCE rate was observed
(56.8 vs 42.5%, p<0.01; table 4). The same pattern was
observed for ICE (table 5 and ﬁgure 1B), except that
the p value for interaction did not reach signiﬁcance.
The risk for MCE rose signiﬁcantly between the
second and the third hsCRP quartile (HR 1.28, p<0.05)
and remained elevated (table 4), while the risk for ICE
increased between the ﬁrst and the second quartile (HR
1.64, p<0.05; table 5).
The addition of hsCRP (baseline and 1-year changes)
to the basic model improved C-statistics from 0.57 to
0.60 (p<0.05) (table 6).
The addition of hsCRP (baseline and 1-year changes)
to the basic model resulted in an improvement in con-
tinuous NRI of 0.24 (95% CI 0.13 to 0.38), continuous
NRI for events 0.03 and continuous NRI for non-events
Table 2 Effect of treatment on lipids and markers of inflammation
Variable Allocation Baseline Year 1 Paired p value One-year changes
hsCRP (mg/L) Treatment 2.1 (0.9–4.1)* 1.2 (0.6–2.4)* <0.001 1.76 (0.0–4.4)**
Placebo 2.2 (0.9–4.9) 1.8 (0.85–4.35) 0.003 0.00 (−1.5–2.1)
Total cholesterol (mmol/L) Treatment 5.72 (5.05–6.42) 3.39 (2.95–3.91)** <0.001 2.25 (1.7–2.8)**
Placebo 5.67 (4.97–6.37) 5.5 (4.92–6.2) <0.001 0.13 (−0.3–0.5)
LDL-cholesterol (mmol/L) Treatment 3.49 (2.94–4.15) 1.32 (1.02–1.69)** <0.001 2.13 (1.6–2.6)**
Placebo 3.46 (2.92–4.08) 3.34 (2.81–3.92) <0.001 0.12 (−0.2–0.4)
White cell count (109/L) Treatment 5.72 (5.05–6.42)
Placebo 5.8 (4.9–6.9)
AST (U/L) Treatment 16 (14–19) 19 (16–23)** <0.001 −3.20 (−5.0–0.0)**
Placebo 16 (14–19) 16 (14–19) 0.59 0.00 (−2.0–2.0)
Between groups (allocation): *p<0.05; **p<0.001.
Data are shown as median values and IQR. One-year changes are shown at baseline minus year 1 values.
AST, aspartate aminotransferase; hsCRP, high-sensitive C reactive protein; LDL, low-density lipoproteins.
Table 3 Cox regression models predicting major cardiovascular and ischaemic events
Variable
Cox regression
model predicting
major cardiovascular events p Value
Cox regression model
predicting ischaemic events p Value
Baseline hsCRP (mg/L) 1.1 (1.04–1.17) 0.002 1.1 (1.00–1.20) 0.043
Increase in hsCRP (mg/L) 1.17 (1.1–1.24) <0.001 1.19 (1.12–1.25) <0.001
Hypertension 2.12 (1.23–3.67) 0.007
Treatment allocation 0.91 (0.75–1.1) 0.99 0.87 (0.67–1.13) 0.283
Gender 1.01 (1–1.02) 0.33 0.68 (0.52–0.89) 0.005
Age 1.01 (1–1.02) 0.12 1.05 (1.03–1.07) <0.001
Heart rate (beats/min) 1.01 (1–1.02) 0.01
WCC (109/L) 1.12 (1.03–1.22) 0.010
Univariate (unadjusted)
Baseline hsCRP (mg/L) 1.06 (1.01–1.12)* 0.021 1.13 (1.06–1.21)** <0.001
Increase in hsCRP (mg/L) 1.12 (1.06–1.19)** <0.001 1.19 (1.1–1.29)** <0.001
*p<0.05; **p<0.001.
hsCRP, high-sensitivity C reactive protein; WCC, white cell count.
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Figure 1 Event-free survival according to baseline and 1-year changes in high-sensitive C reactive protein (hsCRP). Survival
free of (A) major cardiovascular event (MCE) and (B) ischaemic cardiovascular event (ICE) according to baseline and 1-year
changes in hsCRP.
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Table 4 Major cardiovascular event rates and HRs according to quartiles of baseline hsCRP in the whole cohort as well as in patients with increasing or decreasing
hsCRP
Baseline hsCRP One-year changes in hsCRP from baseline
Increase Decrease
Quartiles of
baseline hsCRP N HR
Events per 1000
patient-years N HR
Events per 1000
patient-years N HR
Events per 1000
patient-years
1st quartile 422 1 83 171 1 92 231 1 75
2nd quartile 412 1.1 (0.87 to 1.39) 95 143 1.2 (0.84 to 1.71) 119 232 1.03 (0.73 to 1.44) 78
3rd quartile 388 1.28 (1.02 to 1.62)* 116 85 1.31 (0.87 to 1.96) 134 258 1.28 (0.94 to 1.75) 102
4th quartile 396 1.19 (0.94 to 1.51) 106 74 1.62 (1.09 to 2.4)* 168 280 1.07 (0.78 to 1.47) 82
1st–3rd quartile 1222 1.06 (0.88 to 1.28) 399 1.06 (0.88 to 1.28)* 721 0.96 (0.75 to 1.23)
*p<0.05.
hsCRP, high-sensitivity C reactive protein.
Table 5 Ischaemic cardiovascular event rates and HRs according to quartiles of baseline hsCRP in the whole cohort as well as in patients with increasing or decreasing
hsCRP
Baseline hsCRP One-year changes in hsCRP from baseline
Increase Decrease
Quartiles of
baseline hsCRP N HR
Events per 1000
patient-years N HR
Events per 1000
patient-years N HR
Events per 1000
patient-years
1st quartile 422 1 29 171 1 37 231 1 21
2nd quartile 412 1.64 (1.15 to 2.33)* 50 143 1.61 (0.97 to 2.67) 64 232 1.74 (1.01 to 3.02)* 37
3rd quartile 388 1.54 (1.08 to 2.22)* 48 85 1.47 (0.81 to 2.66) 58 258 1.75 (1.02 to 2.99)* 38
4th quartile 396 1.73 (1.21 to 2.46)* 52 74 2.13 (1.22 to 3.71)* 85 280 1.77 (1.04 to 3.01)* 37
1st–3rd quartile 1222 1.24 (0.96 to 1.61) 399 1.62 (1.03 to 2.55) 721 1.18 (0.82 to 1.69)
*p<0.05.
hsCRP, high-sensitivity C reactive protein.
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0.20. The IDI was 0.03 (p=0.07). For ICE (table 7), the
C-statistics improved from 0.65 to 0.68 (p<0.05), and
continuous NRI improved by 0.26 (95% CI 0.02 to 0.39),
when adding hsCRP (baseline and 1-year changes) to
the basic model. Baseline hsCRP alone did not improve
prediction of MCE or ICE signiﬁcantly.
DISCUSSION
This study has two new observations relevant for the role
of inﬂammation in aortic valve stenosis. First, elevated
baseline hsCRP as well as a 1-year increase in hsCRP pre-
dicted MCE independently of traditional cardiovascular
risk factors because an increase in hsCRP was strongly asso-
ciated with more MCE in patients with elevated baseline
hsCRP. Second, the beneﬁcial effect of simvastatin and eze-
temibe on ICE seemed to be related to a reduction in low-
grade inﬂammation rather than a reduction in lipids.
Elevated baseline hsCRP as well as a 1-year increase in
hsCRP predicted outcome independently of traditional
cardiovascular risk factors
To the best of our knowledge, this is the largest study
investigating the prognostic importance of hsCRP in
patients with asymptomatic mild to moderate AS to date.
In the present study, baseline hsCRP as well as a 1-year
increase in hsCRP predicted the combined end point
independently of the traditional risk factors. In a study
performed by Solberg et al,18 hsCRP predicted cardiovas-
cular events in patients with severe AS signiﬁcantly in uni-
variate analysis, but not when included in a multivariate
analysis. In a small study by Dichtl et al,19 CRP remained
signiﬁcant in multivariate analysis, with an HR of 1.6. The
study by Dichtl et al19 resembled the SEAS study with
regard to inclusion criteria and baseline characteristics,
while the population in the study by Solberg et al18 had
more advanced disease, an incidence of coronary artery
disease of 50% and all were referred for AVR. However, in
the ASTRONOMER trial, the only other study with
in-treatment CRP values, although not to the best of our
knowledge reported, CRP did not predict outcome and
there was no difference in survival according to baseline
CRP.20 The baseline characteristics in ASTRONOMER
were different from those in SEAS.21 In total, 48.9% had
congenital bicuspid aortic valves, they were younger and
only fewer were currently smoking at inclusion. Our ﬁnd-
ings complement these studies. In a previous report from
the SEAS study22 evaluating hsCRP as part of developing
a risk score for predicting mortality in patients with
asymptomatic mild to moderate AS, hsCRP also signiﬁ-
cantly predicted mortality.
Furthermore, reduction in hsCRP during the ﬁrst
study year was associated with better outcome independ-
ently of baseline hsCRP and traditional cardiovascular
risk factors. This is the ﬁrst time that an association
between treatment-induced changes in an inﬂammatory
marker and MCE has been demonstrated in a popula-
tion of patients with AS. The beneﬁcial effect of a
decrease in hsCRP during the ﬁrst year of treatment was
largest for those with a baseline hsCRP in the top quar-
tile. Interestingly, the beneﬁcial effect of a decrease in
hsCRP seemed to obliterate the prognostic importance
of baseline hsCRP (tables 4 and 5). These observations
have also been reported in other populations, that is, in
the general population,23 in patients with chronic heart
failure,24 and in patients with non-ST elevation acute cor-
onary syndrome.25
Furthermore, we found that hsCRP added signiﬁcantly
to the model predicting MCE assessed by C-index and con-
tinuous NRI. This suggests that low-grade inﬂammation
assessed by hsCRP might be an important marker of pro-
gression of AS. However, our results need conﬁrmation in
other studies before hsCRP can be used clinically for esti-
mation of cardiovascular risk in participants with AS.
Table 6 Performance of MCE risk models including traditional risk factors with and without hsCRP
C-index (95% CI) p Value NRI (95% CI) IDI (95% CI) p Value
Basic model 0.57 (0.43 to 0.71)
Basic model+baseline hsCRP and
1-year changes
0.60 (0.41 to 0.79) <0.05 0.24 (0.13 to 0.38) 0.03 (0 to 0.07) 0.07
Basic model: age, sex, heart rate, white cell count, tobacco and treatment group.
hsCRP, high-sensitivity C reactive protein; IDI, integrated discrimination improvement; MCE, major cardiovascular event; NRI, net
reclassification improvement.
Table 7 Performance of ICE risk models including traditional risk factors with and without hsCRP
C-index (95% CI) p Value NRI (95% CI) IDI (95% CI) p Value
Basic model 0.65 (0.34 to 0.96)
Basic model+baseline hsCRP
and 1-year changes
0.68 (0.33 to 1.03) <0.05 0.26 (0.02 to 0.39) 0.01 (−0.01 to 0.04) 0.4
Basic model: age, sex, heart rate, white cell count, tobacco and treatment group.
hsCRP, high-sensitivity C reactive protein; ICE, ischaemic cardiovascular event; IDI, integrated discrimination improvement; NRI, net
reclassification improvement.
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The beneficial effect of simvastatin and ezetimibe on ICE
was partly due to reduced hsCRP
Not surprisingly, baseline hsCRP as a marker of low-
grade inﬂammation signiﬁcantly predicted ICE as previ-
ously demonstrated in many other cohorts.7 26 27 When
1-year changes in hsCRP were added to the model, treat-
ment allocation was no longer signiﬁcant in the predic-
tion of ICE. As expected, simvastatin and ezetimibe
treatment reduced the lipid levels, but in Cox regression
analysis changes in neither total nor LDL-cholesterol
were signiﬁcantly associated with ICE. Therefore, our
study indicates that the reduction in ICE was related to
the reduction in inﬂammation and not to changes in
lipids. This corresponds well with previous ﬁndings from
the JUPITER trial.9 However, neither studies were able
to show conclusively whether it was the lipid reduction,
reduced inﬂammation or a combination of the two,
which accounted for the beneﬁcial effect on ICE.
Therefore, further studies are needed to answer this
question. A possible confounder could be the inﬂamma-
tory effects of LDL-cholesterol itself and its contribution
to increased hsCRP.
Limitations
The inclusion and exclusion criteria for the SEAS study
induce some limitations on this study. As this is a non-pre-
speciﬁed explorative substudy no causual relationship
can be established. Additionally preconsisting inﬂamma-
tory diseases or conditions were not considered in
planning the original study design. The participants had
to be asymptomatic, as well as jet velocity between 2.5 and
4 m/s. In addition, participants with known ischaemic
heart disease and diabetes were excluded due to the
placebo comparison of the study. However, the study
population was otherwise not at low cardiovascular risk
due to the relative high age, hyperlipidaemia, obesity,
smoking and high prevalence of hypertension10 and did
reﬂect patients seen in the daily clinic. As the ﬁndings
were generated from post hoc analysis, any causal rela-
tionship cannot be inferred from these results.
CONCLUSION
Although treatment with simvastatin 40 mg and ezeti-
mibe 10 mg reduced both cholesterol and hsCRP, the
treatment-associated reduction in ICE seemed to be
related to the reduction in hsCRP rather than in choles-
terol. hsCRP reduction was associated with fewer MCE
and the prognostic beneﬁt of a 1-year reduction in
hsCRP was larger in patients with high baseline hsCRP.
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